A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma

Genentech, Inc.1,953 enrolled

Overview

This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either previously untreated or treated \<=4 months prior to enrollment.

Study Type

OBSERVATIONAL

Enrollment

1,953

Conditions

Colorectal Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed Informed Consent and Authorization document * Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum * Receiving Avastin as a component of first-line chemotherapy * First-line chemotherapy plus Avastin initiated \<=4 months prior to enrollment in the study Exclusion Criteria: * Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.

Locations (1)

Genentech Central Contact

South San Francisco, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.